Ryvu Therapeutics S.A. (WSE:RVU)

Market Cap	523.67M -31.1%
Revenue (ttm)	87.70M -14.0%
Net Income	-101.23M
EPS	-4.38
Shares Out	23.12M
PE Ratio	n/a
Forward PE	8.47
Dividend	n/a
Ex-Dividend Date	n/a

Volume	248,124
Average Volume	25,392
Open	22.00
Previous Close	22.65
Day's Range	18.70 - 22.30
52-Week Range	18.88 - 33.35
Beta	0.59
RSI	24.69
Earnings Date	May 21, 2026

About Ryvu Therapeutics

Ryvu Therapeutics S.A., a clinical stage biopharmaceutical company, engages in developing of novel small molecule therapies for treatment in oncology. Its lead candidate, RVU120, is a CDK8 kinase inhibitor with potential for development in hematological malignancies and solid tumors, which is in Phase 1b study for the treatment of acute myeloid leukemia and myelodysplastic syndrome. The company's products also include SEL24/MEN1703, a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group that is in Phase 2 clinical trial for the treatme...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 228
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: RVU

Financial Performance

In 2025, Ryvu Therapeutics's revenue was 87.70 million, a decrease of -13.98% compared to the previous year's 101.96 million. Losses were -101.23 million, -9.16% less than in 2024.